Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Provention Bio Inc (PRVB)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Provention Bio's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
Provention Bio historical data, for real-time data please try another search
24.980 +0.000    +0.00%
26/04 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 24.980 - 25.000
Provention Bio 24.980 +0.000 +0.00%

NASDAQ:PRVB Financials

 
A brief overview of the NASDAQ:PRVB financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Provention Bio Inc over time.

Provention Bio, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 28.63 million compared to USD 27.02 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 0.43 a year ago.For the nine months, net loss was USD 80.29 million compared to USD 88.6 million a year ago. Basic loss per share from continuing operations was USD 1.14 compared to USD 1.41 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

PRVB Income Statement

Gross margin TTM -
Operating margin TTM -
Net Profit margin TTM -
Return on Investment TTM -
 Total Revenue  Net Income
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Total Revenue 10.81 0.756 0.746 0.58
Gross Profit -15.23 -15.58 -15.83 -16.78
Operating Income -40.17 -29.08 -29.83 -29.08
Net Income -33.28 -28.63 -29.69 -21.97

PRVB Balance Sheet

Quick Ratio MRQ -
Current Ratio MRQ -
LT Debt to Equity MRQ -
Total Debt to Equity MRQ -
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Total Assets 236.86 193.91 104.35 122.46
Total Liabilities 115.01 49.14 25.67 28.25
Total Equity 121.85 144.77 78.68 94.21

PRVB Cash Flow Statement

Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow  -8.83%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -7.98 -23.97 -28.44 -15.03
Cash From Investing Activities -51.27 -46.23 -0.226 9.6
Cash From Financing Activities 0.905 114.69 11.64 2.15
Net Change in Cash -58.34 44.5 -17.03 -3.28
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

PRVB Comments

Write your thoughts about Provention Bio Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
zoltán csorba
zoltán csorba Mar 13, 2023 11:21PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
go 10$
Reply
0 0
Report
John Berry
John Berry Mar 13, 2023 4:31AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Easy 300% winner
Reply
1 2
Report
Mavi Yesil
Mavi Yesil Feb 13, 2023 12:24PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I think they will produce insulin as pills
Reply
0 0
Report
Mavi Yesil
Mavi Yesil Feb 13, 2023 12:05PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The convenience foods we consume make us suffer from diabetes. Diabetes is also common in children under the age of 10. Sugar is the disease of humanity. Everyone around me uses insulin. Medicines for diabetes are humanity's greatest hope. This company will do great things. drug production is great. It gives hope and expectation.
Reply
0 0
Report
John Avenetti
John Avenetti Aug 05, 2021 1:40PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
earnings? they're in clinical trials.
Reply
1 0
Report
Tim Crum
Tim Crum May 27, 2021 5:54PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
going to pop tomorrow
Reply
0 0
Report
John Avenetti
John Avenetti May 27, 2021 5:54PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
it seems likely
Reply
0 0
Report
Tim Crum
Tim Crum May 27, 2021 5:54PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
why is premarket down? doesn't make sense. I see this as likely being approved as long as the PK data with FDA gets sorted out.
Reply
0 0
Report
Szoka Krisztian
Szoka Krisztian May 25, 2021 2:46PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://finance.yahoo.com/news/prvb-shareholder-alert-bronstein-gewirtz-140000371.html
Reply
0 0
Report
Sean ONeal
Sean ONeal Mar 11, 2021 6:55PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
interesting info https://www.jdrf.org/blog/2020/06/15/updates-teplizumab-trial-going-believe-results/
Reply
0 0
Report
Tom Daniel
Tom Daniel Mar 11, 2021 6:55PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
stock price doesn't GAF
Reply
0 0
Report
Sky Emperor
SkyEmperor Dec 10, 2020 10:13AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Finally some movements
Reply
3 0
Report
Sky Emperor
SkyEmperor Nov 19, 2020 8:16AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
So i expected yesterday to have some impact the presentation,now what happened anyone knows? No big changes, still in range of 15
Reply
1 0
Report
Gene Emory
Gene Emory Nov 19, 2020 8:16AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Hold till news of fda approval. I see $100 by end of 2021. Happy trading...
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email